Image

Global Point-of-Care Testing (POCT) Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Jul 2022
  • Global
  • 357 Pages
  • No of Tables: 59
  • No of Figures: 170

Global Point-of-Care Testing (POCT) Market, By Product (Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products, Rapid Coagulation Testing and Other POC Products), Application (Blood Transfusion, Cardiac Monitoring, Coagulation, Blood Glucose, Haematology, Non- Invasive SPO2 Monitoring, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Vital Sign Monitoring and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays), Prescription Mode (Prescription-Based Testing and OTC Testing), Testing Type (Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays and Hematology), End-User (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgery Centers and Others), Distribution Channel (Direct Tender and Retail Pharmacies) – Industry Trends and Forecast to 2029

 

Point-of-Care Testing (POCT) Market

Market Analysis and Size

Point-of-care testing is defined as testing that may be done in close proximity to the patient and allows a medical choice to be taken immediately based on the results and monitoring. Point-of-care testing (POCT), also known as with-patient testing, allows doctors to assess accurate real-time, lab-quality diagnostic results in minutes rather than hours. It guarantees that patients get the most effective and efficient care possible, whenever and wherever they need it.

Data Bridge Market Research analyses that the point-of-care testing (POCT) market which was USD 29 billion in 2021, would rocket up to USD 64.46 billion by 2029, and is expected to undergo a CAGR of 10.5% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

POC tests are not as highly preferred as central laboratory tests because of low volume and high cost. This puts additional strain on the billing system, which must give distinct codes for POC tests. This might result in billing errors by inexperienced or newly hired employees and failure to enter data into the data management system due to mismatched test codes.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Product (Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Disease Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-Abuse Testing Products, Fecal Occult Testing Products, Rapid Coagulation Testing and Other POC Products), Application (Blood Transfusion, Cardiac Monitoring, Coagulation, Blood Glucose, Haematology, Non- Invasive SPO2 Monitoring, Non- Invasive PCO2 Monitoring, Whole Blood Analysis, Vital Sign Monitoring and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Dipsticks, Microfluidics, Molecular Diagnostics and Immunoassays), Prescription Mode (Prescription-Based Testing and OTC Testing), Testing Type (Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays and Hematology), End-User (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgery Centers and Others), Distribution Channel (Direct Tender and Retail Pharmacies)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), B.D. (U.S.), Siemens Healthcare Private Limited (Germany), Bio-Rad Laboratories, Inc. (U.S.), Danaher (U.S.), Sekisui Diagnostics (U.S.), Trinity Biotech (Ireland), bioMérieux (France), EKF Diagnostics (Germany), AccuBioTech Co., Ltd. (China), Instrumentation Laboratory (U.S.), Beckman Coulter, Inc. (U.S.), PTS Diagnostics (U.S.), Nova Biomedical (U.S.), Chembio Diagnostics, Inc. (U.S.), Quidel Corporation (U.S.) and Sienco, Inc (U.S.)

Market Opportunities

  • Technological advancement in lateral flow assay

  • Advances in component materials

Point-of-Care Testing (POCT) Market Dynamics

Drivers

  • Rising trend in prevalence of diseases

Chronic diseases and acute infections are on the rise in developing countries, owing to a lack of health awareness, poor medical infrastructure, and a sedentary lifestyle, among other causes. As a result of these circumstances, diagnosis and treatment are delayed, as the quality of care obtained. The need for point-of-care tests for rapid diagnosis is growing due to their convenience of use, cost-effectiveness, and small product size.

  • Benefits related with OTC-based test

The point of care testing market for T.C. tests is expected to develop at a 7.1% CAGR through 2027, owing to an increase in OTC testing such as pregnancy tests and blood glucose tests that deliver results in a matter of seconds. These examinations do not necessitate the use of a skilled specialist and may be performed by individuals themselves, propelling the industry forward. The First Response kit, for example, is a quick pregnancy test that provides a response in 60 seconds. Accu-Chek active blood glucose metre kits also give customers with readings in 5 seconds, boosting market demand.

  • Increasing incidence rate of diabetes

The rising incidence rate of diabetes and obesity, the point of care testing market for cardio metabolic testing is expected to surpass USD 5.3 billion by 2027. The percentage level of Docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA) in red blood cell membrane is also determined by the cardiometabolic test. This also aids in the identification of new risk factors for cardiac arrest and other heart-related disorders.

Opportunities

  • Technological advancement in lateral flow assay

The industry's growth will be aided by the launch of novel products that will allow for rapid advancement in the research and development (R&D) of point-of-care testing (POCT) diagnostic tools. In addition, advances in component materials, reader technologies, reagents, and sensitivity increase have made quantitative results more possible with the use of lateral flow assay, supporting sector growth.

Restraints/Challenges

  • Lack of alignment with definitive central lab methods

Unsuitable indications for the performance of the test, inappropriate sampling times and techniques, a lack of information about the patient's condition, and other factors such as fasting before functional tests or variations in posture/position during similar tests are all examples of pre-analytical errors for POC testing.

This point-of-care testing (POCT) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the point-of-care testing (POCT) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Point-of-Care Testing (POCT) Market

The growing use of point-of-care tests that can quickly identify COVID-19, the point-of-care diagnostics market will rise significantly in 2022. Point-of-care testing has become an important diagnostic technique due to the necessity for quick diagnostic results. Rapid antigen testing kits that can be utilised efficiently in point-of-care settings are in high demand due to the rapidly increasing number of COVID-19 cases and the growing pressure on governments to enhance patient management. Different significant reasons projected to fuel the long-term growth of the point-of-care diagnostics market are the rising prevalence of other respiratory disorders around the world, the shift toward decentralised diagnostics, and enhanced access to point-of-care devices through online platforms.

Recent Development

 In January 2022, Roche introduced its Cobas Pulse System in select countries accepting the CE Mark. This is the latest generation of linked point-of-care solutions for professional blood glucose management from Roche Diagnostics.

 In October 2021, Thermo Fisher Scientific announced that it had received FDA Emergency Use Authorization (EUA) to run COVID-19 tests with the Spectrum Solutions SpectrumDNA SDNA-1000 collection device, a high-throughput, automated COVID-19 testing system on the Amplitude Solution, using a new saliva sample collection method.

Global Point-of-Care Testing (POCT) Market Scope

The point-of-care testing (POCT) market is segmented on the basis of product, technology, prescription, application, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 Product

  • Glucose Monitoring
  • Strips
  • Meters
  • Lancets
  • Cardiometabolic testing
  • Cardiac marker testing
  • hsTnl
  • BNP
  • D-dimer
  • CK-MB
  • Myoglobin
  • Others
  • Blood gas/electrolytes testing
  • HBA1C testing
  • Infectious disease testing
  • Influenza testing
  • HIV testing
  • Hepatitis C testing
  • Sexually Transmitted Disease (STD) testing
  • Healthcare-Associated Infection (HAI) testing
  • Respiratory infection testing
  • Tropical disease testing
  • Other infectious diseases testing
  • Coagulation testing
  • PT/INR testing
  • Activated Clotting Time (ACT/APTT) testing
  • Pregnancy and fertility testing
  • Pregnancy testing
  • Fertility testing
  • Tumor/Cancer marker testing
  • Urinalysis testing
  • Cholesterol testing
  • Hematology testing
  • Drugs-of-abuse testing
  • Fecal occult testing
  • Others

Technology

  • Lateral flow assays
  • Dipsticks
  • Microfluidics
  • Molecular diagnostics
  • Immunoassays
  • Agglutination assays
  • Flow-through
  • Solid phase
  • Biosensors

Prescription

  • OTC testing
  • Prescription-based testing

Application

  • Cardio metabolic testing
  • Infectious disease testing
  • Nephrology testing
  • Drug-of-Abuse (DoA) testing
  • Blood glucose testing
  • Pregnancy testing
  • Cancer biomarker testing
  • Other applications

 End-user

  • Hospitals
  • Diagnostic centers
  • Research laboratories
  • Home-care settings
  • Others

Distribution Channel

  • Direct tender
  • Retail Pharmacies

Point-of-Care Testing (POCT) Market Regional Analysis/Insights

The point-of-care testing (POCT) market is analysed and market size insights and trends are provided by country, product, technology, prescription, application end-user and distribution channel as referenced above.

The countries covered in the point-of-care testing (POCT) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Healthcare Infrastructure growth Installed base and New Technology Penetration

The point-of-care testing (POCT) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for point-of-care testing (POCT) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the point-of-care testing (POCT) market. The data is available for historic period 2010-2020.

Competitive Landscape and Point-of-Care Testing (POCT) Market Share Analysis

The point-of-care testing (POCT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to point-of-care testing (POCT) market.

Some of the major players operating in the point-of-care testing (POCT) market are:

  • Abbott (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • BD (U.S.)
  • Siemens Healthcare Private Limited (Germany)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Danaher (U.S.)
  • Sekisui Diagnostics (U.S.)
  • Trinity Biotech (Ireland)
  • bioMérieux (France)
  • EKF Diagnostics (Germany)
  • AccuBioTech Co., Ltd. (China)
  • Instrumentation Laboratory (U.S.)
  • Beckman Coulter, Inc. (U.S.)
  • PTS Diagnostics (U.S.)
  • Nova Biomedical (U.S.)
  • Chembio Diagnostics, Inc. (U.S.)
  • Quidel Corporation (U.S.)
  • Sienco, Inc (U.S.)

Research Methodology: Global Point-of-Care Testing (POCT) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLE GLOBAL POINT-OF-CARE TESTING MARKET

TABLE 1 LIST OF DIFFERENT TYPES OF APPROVAL FOR DIFFERENT COUNTRIES TABLE 2 GLOBAL POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 3 GLOBAL CARDIOMETABOLIC MONITORING POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 4 GLOBAL INFECTIOUS DISEASE POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 5 GLOBAL CHOLESTEROL POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 6 GLOBAL POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION) TABLE 7 DISTRIBUTION CHANNEL, DIRECT TENDER, BY REGION, 2015 – 2024 (USD MILLION) TABLE 8 DISTRIBUTION CHANNEL, RETAIL PHARMACY, BY REGION, 2015 – 2024 (USD MILLION) TABLE 9 GLOBAL POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 10 GLOBAL POINT-OF-CARE TESTING MARKET, HOSPITALS, BY REGION 2015– 2024 (USD MILLION) TABLE 11 GLOBAL POINT-OF-CARE TESTING MARKET, CLINICS, BY REGION 2015– 2024 (USD MILLION) TABLE 12 GLOBAL POINT-OF-CARE TESTING MARKET, AMBULATORY CARE, BY REGION 2015– 2024 (USD MILLION) TABLE 13 GLOBAL POINT-OF-CARE TESTING MARKET, HOME HEALTHCARE, BY REGION 2015– 2024 (USD MILLION) TABLE 14 GLOBAL POINT-OF-CARE TESTING MARKET, RESEARCH LABORATORY, BY REGION 2015– 2024 (USD MILLION) TABLE 15 GLOBAL POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015– 2024 (USD MILLION) TABLE 16 GLOBAL POINT-OF-CARE TESTING MARKET, PRESCRIPTION BASED TESTING KITS, BY REGION, 2015– 2024 (USD MILLION) TABLE 17 GLOBAL POINT-OF-CARE TESTING MARKET, OVER THE COUNTER BASED TESTING KITS, BY REGION, 2015– 2024 (USD MILLION) TABLE 18 GLOBAL POINT-OF-CARE TESTING MARKET, BY GEOGRAPHY, 2015 – 2024 (USD MILLION) TABLE 19 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 20 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION) TABLE 21 NORTH AMERICA CARDIOMETABOLIC MONITORING POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 22 NORTH AMERICA INFECTIOUS DISEASE POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024(USD MILLION) TABLE 23 NORTH AMERICA CHOLESTEROL POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024(USD MILLION) TABLE 24 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE 2015 – 2024 (USD MILLION) TABLE 25 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 26 NORTH AMERICA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 27 U.S.POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION) TABLE 28 U.S. POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 29 U.S. POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 30 U.S. POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 31 CANADA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 32 CANADA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 33 CANADA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 34 CANADA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 35 MEXICO POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 36 MEXICO POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 37 MEXICO POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 38 MEXICO POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 39 EUROPE POINT-OF-CARE TESTING MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 40 EUROPE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 41 EUROPE CARDIOMETABOLIC MONITORING POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 42 EUROPE INFECTIOUS DISEASE POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 43 EUROPE CHOLESTEROL POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 44 EUROPE POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE 2015 – 2024 (USD MILLION) TABLE 45 EUROPE POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 46 EUROPE POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 47 GERMANY POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 48 GERMANY POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE 2015 – 2024 (USD MILLION) TABLE 49 GERMANY POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 50 GERMANY POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 51 FRANCE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 52 FRANCE POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE , 2015 – 2024 (USD MILLION) TABLE 53 FRANCE POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 54 FRANCE POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 55 U.K. POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 56 U.K. POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 57 U.K. POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 58 U.K. POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 59 ITALY POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 60 ITALY POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 61 ITALY POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 62 ITALY POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 63 SPAIN POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 64 SPAIN POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 65 SPAIN POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 66 SPAIN POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 67 RUSSIA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 68 RUSSIA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 69 RUSSIA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 70 RUSSIA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 71 TURKEY POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 72 TURKEY POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 73 TURKEY POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 74 TURKEY POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 75 BELGIUM POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 76 BELGIUM POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 77 BELGIUM POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 78 BELGIUM POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 79 NETHERLANDS POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 80 NETHERLANDS POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 81 NETHERLANDS POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 82 NETHERLANDS POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 83 SWITZERLAND POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 84 SWITZERLAND POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 85 SWITZERLAND POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 86 SWITZERLAND POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015–2024 (USD MILLION) TABLE 87 REST OF EUROPE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 88 APAC POINT-OF-CARE TESTING MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 89 APAC POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 90 APAC CARDIOMETABOLIC MONITORING POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 91 APAC INFECTIOUS DISEASE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 92 APAC CHOLESTEROL POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION) TABLE 93 APAC POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 94 APAC POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 95 APAC POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL , 2015– 2024 (USD MILLION) TABLE 96 JAPAN POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 97 JAPAN POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE , 2015 – 2024 (USD MILLION) TABLE 98 JAPAN POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 99 JAPAN POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 100 CHINA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 101 CHINA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE , 2015 – 2024 (USD MILLION) TABLE 102 CHINA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 103 CHINA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 104 SOUTH KOREA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 105 SOUTH KOREA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 106 SOUTH KOREA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 107 SOUTH KOREA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 108 INDIA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 109 INDIA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 110 INDIA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 111 INDIA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL , 2015– 2024 (USD MILLION) TABLE 112 AUSTRALIA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 113 AUSTRALIA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 114 AUSTRALIA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 115 AUSTRALIA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 116 SINGAPORE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 117 SINGAPORE POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 118 SINGAPORE POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 119 SINGAPORE POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 120 THAILAND POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 121 THAILAND POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 122 THAILAND POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 123 THAILAND POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 124 MALAYSIA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 125 MALAYSIA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 126 MALAYSIA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 127 MALAYSIA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 128 INDONESIA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 129 INDONESIA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 130 INDONESIA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 131 INDONESIA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 132 PHILIPPINES POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 133 PHILIPPINES POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 134 PHILIPPINES POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 135 PHILIPPINES POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 136 REST OF APAC POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 137 MEA POINT-OF-CARE TESTING MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 138 MEA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION) TABLE 139 MEA CARDIOMETABOLIC MONITORING POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 140 MEA INFECTIOUS DISEASE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE,2015 – 2024 (USD MILLION) TABLE 141 MEA CHOLESTEROL POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 142 MEA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 143 MEA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 144 MEA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 145 SOUTH AFRICA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 146 SOUTH AFRICA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 147 SOUTH AFRICA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 148 SOUTH AFRICA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015–2024 (USD MILLION) TABLE 149 SAUDI ARABIA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 150 SAUDI ARABIA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 151 SAUDI ARABIA POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 152 SAUDI ARABIA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 153 UAE POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 154 UAE POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE , 2015 – 2024 (USD MILLION) TABLE 155 UAE POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 156 UAE POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 157 REST OF MEA POINT-OF-CARE TESTING MARKET, BY PRODUCTTYPE, 2015 – 2024 (USD MILLION) TABLE 158 SOUTH AMERICA: HEALTHCARE SPENDING (USD PER HEAD) TABLE 159 SOUTH AMERICA POINT-OF-CARE TESTING MARKET, BY COUNTRY,2015 – 2024 (USD MILLION) TABLE 160 SOUTH AMERICA POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 161 SOUTH AMERICA CARDIOMETABOLIC MONITORING POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 162 SOUTH AMERICA INFECTIOUS DISEASE POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024(USD MILLION) TABLE 163 SOUTH AMERICA CHOLESTEROL POINT-OF-CARE TESTING MARKET, BY TYPE, 2015 – 2024 (USD MILLION) TABLE 164 SOUTH AMERICA POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 165 SOUTH AMERICA POINT-OF-CARE TESTING MARKET, BY END-USER, 2015 – 2024 (USD MILLION) TABLE 166 SOUTH AMERICA POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) TABLE 167 BRAZIL POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION) TABLE 168 BRAZIL POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE, 2015 – 2024 (USD MILLION) TABLE 169 BRAZIL POINT-OF-CARE TESTING MARKET, BY END USER, 2015– 2024 (USD MILLION) TABLE 170 BRAZIL POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION)

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The global point-of-care testing (POCT) market competitive landscape provides details by competitor such as company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance.
The major players covered in the point-of-care testing (POCT) market report are Abbott,  F. Hoffmann-La Roche Ltd, Siemens AG, Beckman Coulter, Inc., BD, Johnson & Johnson Services, Inc., Instrumentation Laboratory, PTS Diagnostics, Abaxis, Medtronic, Accriva Diagnostics, Opti Medical, Sienco, Inc., Alpha Scientific Electronics, AccuBioTech Co., Ltd., ACON Laboratories, Inc., Acrongenomics Inc., bioMérieux SA, Biomerica, Inc., Binx Health, Inc., Alfa Scientific Designs, Inc., Bio-Rad Laboratories, Inc., Medica Corporation, Nova Biomedical among other domestic and global players.
The Point-of-Care Testing (POCT) Market is to grow at a CAGR of 10.5% during the forecast by 2029.
The Point-of-Care Testing (POCT) Market value is expected USD 64.46 billion by 2029.